Commercial and scientific update
ProBiotix Health was incorporated on 4 November 2021 under the name ProBiotix Limited with registered number 13723211 under the Companies Act 2006 and was renamed ProBiotix Health Limited and re-registered as a public limited company on 31 March 2022. ProBiotix Health plc is the holding company of ProBiotix Limited, which it acquired on 31 March 2022.
ProBiotix was established by OptiBiotix Health Plc to develop probiotics to tackle cardiovascular disease and other lifestyle conditions which are affecting growing numbers of people across the world. Since its creation, ProBiotix has become a global leader in microbiome modulating probiotics for use in functional foods, supplements and biotherapeutics.
Independent clinical studies¹ have shown that ProBiotix’s principal product, LP-LDL®, can reduce key cardiovascular risk biomarkers, such as total cholesterol, LDL (bad) cholesterol, and blood pressure, by 36.7 per cent, 13.9 per cent and 5.1 per cent respectively. Since launching its CholBiome® products containing LP-LDL® in May 2017, ProBiotix has signed over 41 agreements and its products are now commercialised in 60 countries.
LPL-DL® was designated Generally Recognized As Safe ("GRAS") by an independent Expert GRAS Panel in the United States in February 2019, which extends its applications from use as a supplement to use as a functional ingredient in a wide range of food, dairy, and beverage products in the USA.
The Directors believe that an investment in the Company represents an opportunity to invest in an innovative technology that is underpinned by a significant portfolio of Intellectual Property Rights, supported by an experienced board, and applicable to a range of markets.
ProBiotix Health is a subsidiary of AIM listed OptiBiotix Health Plc. OptiBiotix was formed in March 2012 by Stephen O’Hara, the Company’s Chief Executive, to develop compounds which modify the human microbiome to prevent and manage human disease.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
OptiBiotix has a strategy of bringing its divisions to maturity, through scientific development, to create self-sustaining commercial entities with the potential for an exit or public listing.
In support of this strategy, OptiBiotix established ProBiotix in 2018, recognising that its probiotics business had achieved sufficient scientific and commercial maturity, with rapidly growing revenue streams, to justify a standalone commercial operation.
On 31 March 2022, ProBiotix Health acquired ProBiotix in a share for share exchange.
ProBiotix Health anticipating "big commercial opportunities" during 2023
Group CEO Stephen O’Hara and CEO Steen Anderson | 04 January 2023